Related Experiment Videos
[Diagnosis and therapy of micromolecular plasmocytomas -- a case report]
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|April 1, 1980
Abstract:
It is reported on the symptomatology, diagnostics and therapy in a 54-year-old patient with a micromolecular plasmocytoma of kappa-type. Here particularly the impressionable improvement of the clinical picture after an intermitting impact therapy with melphalan (alkeran) - prednisolone in a period of treatment of approximately 2 years is emphasized.
Insights
This case study highlights a 54-year-old patient with kappa-type micromolecular plasmacytoma. Intermittent melphalan-prednisolone therapy led to significant clinical improvement over two years.
Area of Science:
- Hematology
- Oncology
Background:
- Micromolecular plasmacytoma is a rare plasma cell disorder.
- Kappa-type light chain involvement is a specific subtype.
Observation:
- A 54-year-old patient presented with symptoms of micromolecular plasmacytoma.
- Diagnostic workup confirmed kappa-type plasmacytoma.
Findings:
- The patient received intermittent impact therapy with melphalan (Alkeran) and prednisolone.
- Remarkable clinical improvement was observed during the approximately 2-year treatment period.
Implications:
- This case suggests intermittent melphalan-prednisolone therapy can be effective for kappa-type micromolecular plasmacytoma.
- Further research into optimal treatment strategies for this rare condition is warranted.